STOCK TITAN

Adagene Inc. - $ADAG STOCK NEWS

Welcome to our dedicated page for Adagene news (Ticker: $ADAG), a resource for investors and traders seeking the latest updates and insights on Adagene stock.

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company specializing in the discovery and development of novel antibody-based cancer immunotherapies. Co-founded by two serial entrepreneurs, Adagene aims to become a leader in antibody discovery and engineering. The company has developed a proprietary Dynamic Precision Library (DPL), showcasing its capabilities through a unique pipeline of innovative antibody therapeutics advancing into clinical trials.

The company's proprietary technologies, including NEObody™, SAFEbody®, and POWERbody™, enable the design of therapeutic antibody candidates with functional epitopes and cross-reactivity across species. These innovations are particularly focused on cancer immunotherapy, where Adagene’s pipeline features monoclonal antibody drugs targeting various cancers.

Adagene has raised over $86 million through three series of financing, with significant investments from F-Prime Capital, Eight Roads Ventures China, 6 Dimensions Capital, GP Healthcare Capital, Sequoia China, and New World TMT. The company utilizes computational biology and artificial intelligence to address unmet patient needs, striving to transform the discovery and development of therapies with enhanced safety and efficacy profiles.

One of Adagene’s key advancements is the development of ADG126, a masked anti-CTLA-4 SAFEbody, which is currently in clinical trials. Recent data highlighted no dose-limiting toxicities and compelling safety when combined with anti-PD-1 therapy. The results indicated tumor shrinkage in cold tumors and partial responses in multiple tumor types. Another notable candidate, ADG116, an unmasked anti-CTLA-4 NEObody, has also shown promising safety and anti-tumor activity in clinical trials.

Adagene’s strategic collaborations with global biopharmaceutical companies, including Roche, Sanofi, and Exelixis, emphasize the commercial potential of its antibody technologies. These partnerships leverage Adagene's platform for developing advanced therapies, including antibody-drug conjugates and bispecific antibodies, addressing a wide range of cancer types.

Financially, Adagene reported a cash balance of $143.8 million at the end of 2022, supporting streamlined operations into 2025. The company continues to prioritize its clinical programs and collaborations, aiming to maximize the therapeutic potential of its proprietary technologies.

For more information, please visit Adagene’s investor website.

Rhea-AI Summary

Adagene (Nasdaq: ADAG) will participate in multiple investor conferences in June 2024. CEO and Chairman, Peter Luo, Ph.D., will provide company updates, particularly on the ADG126 SAFEbody® anti-CTLA-4 progress. The Jefferies Global Healthcare Conference in New York City is scheduled for June 5, followed by the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 13. Lastly, the HC Wainwright 2nd Annual Immune Cell Engager Virtual Conference will be held on June 25. Investors can access live webcasts and replays on Adagene's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
conferences
-
Rhea-AI Summary
Adagene Inc. reports strong financial results for 2023, highlighting the success of its masked anti-CTLA-4 SAFEbody ADG126 in treating metastatic colorectal cancer. The company's cash balance of $110 million supports operations until 2026. Clinical data shows promising results in MSS CRC patients, with a focus on higher dosing and combination therapies. Collaborations with Exelixis and Sanofi demonstrate the versatility of Adagene's platform. Positive pipeline developments include favorable safety profiles for ADG116 and ADG206, with ongoing clinical trials and potential for further expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Adagene Inc. appoints global oncology expert Dr. Heinz-Josef Lenz to its Scientific and Strategic Advisory Board. Dr. Lenz emphasizes the potential of anti-CTLA-4 therapy in treating microsatellite stable colorectal cancer, highlighting the promising results of ADG126 in combination with pembrolizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
management
Rhea-AI Summary
Adagene Inc. announces participation in the Leerink Partners Global Biopharma Conference 2024 to provide an update on its anti-CTLA-4 SAFEbody® ADG126 therapy, with key milestones for 2024. The Chairman, CEO, and President of R&D will present at the conference on March 12 in Miami, Florida.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
conferences
-
Rhea-AI Summary
Adagene Inc. announced progress in the clinical collaboration development program for its anti-CTLA-4 SAFEbody, ADG126, in combination with Merck & Co.'s anti-PD-1 therapy, KEYTRUDA, for patients with metastatic microsatellite-stable colorectal cancer. The company completed the enrollment of 12 additional patients in the ongoing phase 2 dose expansion cohort, plans to evaluate 20 mg/kg loading doses of ADG126, and has received clearance from China’s Center for Drug Evaluation to initiate clinical evaluation of ADG126 in combination with pembrolizumab. Data from the ongoing clinical trial is anticipated throughout 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
none
-
Rhea-AI Summary
Adagene Inc. announced promising clinical data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium. The data from the first tranche of MSS CRC patients treated with ADG126 showed clinical benefit, with preliminary survival analysis indicating best-in-class median progression-free survival (PFS) of seven months. The company also revealed plans for additional data from these patients throughout 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
none
Rhea-AI Summary
Adagene Inc. (Nasdaq: ADAG) announced interim results in MSS CRC suggesting that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses, overcoming safety-limited efficacy challenges. The poster presentation at the ASCO 2024 Gastrointestinal Cancers Symposium will feature results of a phase 1b/2 study of ADG126 in combination with pembrolizumab in patients with metastatic microsatellite-stable colorectal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
conferences
-
Rhea-AI Summary
Adagene Inc. presented new data on its anti-CTLA-4 SAFEbody ADG126 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The data demonstrated that ADG126 is effective at targeting CTLA-4 within the tumor microenvironment, resulting in a wider therapeutic index compared to ipilimumab when combined with anti-PD-1 therapies. The optimal dose of ADG126 at 10 mg/kg every three weeks plus pembrolizumab showed dose-dependent efficacy without a significant increase in treatment-related adverse events. A clinical case example showed a confirmed partial response in a patient with advanced/metastatic MSS CRC. ADG126 may provide greater clinical benefit than ipilimumab in combination with anti-PD-1 in both 'hot' and 'cold' tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.04%
Tags
none
Rhea-AI Summary
Adagene Inc. to participate in investor and scientific conferences, including SITC webinar on September 22
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
conferences

FAQ

What is Adagene's main focus?

Adagene focuses on the discovery and development of novel antibody-based cancer immunotherapies.

What technologies has Adagene developed?

Adagene has developed the Dynamic Precision Library (DPL) platform, including NEObody™, SAFEbody®, and POWERbody™ technologies.

Who are Adagene's significant investors?

Significant investors include F-Prime Capital, Eight Roads Ventures China, 6 Dimensions Capital, GP Healthcare Capital, Sequoia China, and New World TMT.

What is the status of Adagene's clinical candidate ADG126?

ADG126, a masked anti-CTLA-4 SAFEbody, is in clinical trials, showing no dose-limiting toxicities and compelling safety in combination with anti-PD-1 therapy.

What are some of Adagene's strategic collaborations?

Adagene has strategic collaborations with Roche, Sanofi, and Exelixis to leverage its antibody technologies for developing advanced cancer therapies.

What financial position did Adagene report at the end of 2022?

Adagene reported a cash balance of $143.8 million at the end of 2022, supporting operations into 2025.

Where can I find more information about Adagene?

For more information, visit Adagene's investor website at https://investor.adagene.com.

What is the significance of Adagene's technology collaborations?

These collaborations emphasize the commercial potential of Adagene's antibody technologies in developing advanced therapies, including antibody-drug conjugates and bispecific antibodies.

Who co-founded Adagene?

Adagene was co-founded by two serial entrepreneurs.

What are the main therapeutic areas targeted by Adagene's pipeline?

Adagene's pipeline primarily targets various cancers using antibody-based immunotherapies.

Adagene Inc.

Nasdaq:ADAG

ADAG Rankings

ADAG Stock Data

118.34M
12.99M
4.19%
16.13%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Suzhou